一种可预测危重外科脓毒症患者临床结局的转录组严重程度指标
该研究为回顾性验证队列分析,在单中心学术健康中心ICU纳入335例危重成人外科脓毒症患者,于脓毒症诊断后24小时采集全血,用29个信使RNA分类器(Inflammatix-Severity-2)在CLIA认证诊断实验室经NanoString FLEX平台检测。在符合Sepsis-3标准的患者中,该评分预测继发感染的AUC为0.71、预测不良临床结局的AUC为0.75,显著优于C反应蛋白、绝对淋巴细胞计数、总白细胞计数、年龄和Charlson共病指数(p<0.05),优于白细胞介素-6和急性生理与慢性健康评估II但未达显著。多因素logistic回归显示,仅Charlson共病指数(AUC 0.80)或急性生理与慢性健康评估II(AUC 0.81)与Inflammatix-Severity-2联合可显著改善不良临床结局预测,与Charlson共病指数联合预测30天死亡的AUC为0.79。作者认为,将快速检测的转录组指标与临床或生理指标联合,可能优化基于风险资源配置和管理调整。
要点
- 在335例危重成人外科脓毒症患者中,诊断后24小时全血Inflammatix-Severity-2评分预测继发感染AUC 0.71、不良临床结局AUC 0.75,均显著优于C反应蛋白、绝对淋巴细胞计数、总白细胞计数、年龄和Charlson共病指数(p<0.05)。
- Inflammatix-Severity-2预测继发感染和不良临床结局优于白细胞介素-6和急性生理与慢性健康评估II,但差异未达统计学显著。
- 仅Charlson共病指数(AUC 0.80)或急性生理与慢性健康评估II(AUC 0.81)与Inflammatix-Severity-2联合可显著改善不良临床结局预测;与Charlson共病指数联合预测30天死亡的AUC为0.79。
- 作者认为,Inflammatix-Severity-2评分升高的脓毒症住院患者若合并基础共病,可能是旨在降低继发感染和不良临床结局风险的临床干预的理想候选人群。
适用人群与场景
- 单中心学术健康中心ICU的危重成人外科脓毒症患者,共335例,符合Sepsis-3标准。
研究设计与关键结果
- 回顾性验证队列分析,单中心学术健康中心ICU,纳入335例危重成人外科脓毒症患者,无干预。
- 脓毒症诊断后24小时采集全血于PAXgene Blood RNA采集管,用29个信使RNA分类器(Inflammatix-Severity-2)在CLIA认证诊断实验室经NanoString FLEX平台分析。
- 在符合Sepsis-3标准的患者中,Inflammatix-Severity-2评分预测继发感染的AUC为0.71,预测不良临床结局的AUC为0.75,显著优于C反应蛋白、绝对淋巴细胞计数、总白细胞计数、年龄和Charlson共病指数(p<0.05)。
- Inflammatix-Severity-2预测继发感染和不良临床结局优于白细胞介素-6和急性生理与慢性健康评估II,但差异未达统计学显著。
- 多因素logistic回归分析显示,仅Charlson共病指数(AUC 0.80)或急性生理与慢性健康评估II(AUC 0.81)与Inflammatix-Severity-2联合可显著改善不良临床结局预测;与Charlson共病指数联合预测30天死亡的AUC为0.79。
证据类型、等级与局限
- 证据类型:回顾性验证队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,将快速检测的转录组指标与临床或生理指标联合,可能优化基于风险的资源配置和管理调整,从而可能改善外科脓毒症患者的结局。
- 作者认为,Inflammatix-Severity-2评分升高且合并基础共病的脓毒症住院患者,可能是旨在降低继发感染和不良临床结局风险的临床干预的理想候选人群。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Clinically deployable methods for the rapid and accurate prediction of sepsis severity that could elicit a meaningful change in clinical practice are currently lacking. We evaluated a whole-blood, multiplex host-messenger RNA expression metric, Inflammatix-Severity-2, for identifying septic, hospitalized patients' likelihood of 30-day mortality, development of chronic critical illness, discharge disposition, and/or secondary infections.
DESIGN: Retrospective, validation cohort analysis.
SETTING: Single, academic health center ICU.
PATIENTS: Three hundred thirty-five critically ill adult surgical patients with sepsis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Whole blood was collected in PAXgene Blood RNA collection tubes at 24 hours after sepsis diagnosis and analyzed using a custom 29-messenger RNA classifier (Inflammatix-Severity-2) in a Clinical Laboratory Improvement Amendments certified diagnostic laboratory using the NanoString FLEX platform. Among patients meeting Sepsis-3 criteria, the Inflammatix-Severity-2 severity score was significantly better (p < 0.05) at predicting secondary infections (area under the receiver operating curve 0.71) and adverse clinical outcomes (area under the receiver operating curve 0.75) than C-reactive protein, absolute lymphocyte counts, total WBC count, age, and Charlson comorbidity index (and better, albeit nonsignificantly, than interleukin-6 and Acute Physiology and Chronic Health Evaluation II). Using multivariate logistic regression analysis, only combining the Charlson comorbidity index (area under the receiver operating curve 0.80) or Acute Physiology and Chronic Health Evaluation II (area under the receiver operating curve 0.81) with Inflammatix-Severity-2 significantly improved prediction of adverse clinical outcomes, and combining with the Charlson comorbidity index for predicting 30-day mortality (area under the receiver operating curve 0.79).
CONCLUSIONS: The Inflammatix-Severity-2 severity score was superior at predicting secondary infections and overall adverse clinical outcomes compared with other common metrics. Combining a rapidly measured transcriptomic metric with clinical or physiologic indices offers the potential to optimize risk-based resource utilization and patient management adjustments that may improve outcomes in surgical sepsis. Hospitalized patients who are septic and present with an elevated IMX-SEV2 severity score and preexisting comorbidities may be ideal candidates for clinical interventions aimed at reducing the risk of secondary infections and adverse clinical outcomes.
参考来源
- Brakenridge SC, Starostik P, Ghita G, et al. A Transcriptomic Severity Metric That Predicts Clinical Outcomes in Critically Ill Surgical Sepsis Patients. Crit Care Explor. 2021. PMID: 34671746. doi:10.1097/CCE.0000000000000554
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。